Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.64 |
| ▸ | DPP9 | Q86TI2 | 14/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 13/20 | 0.61 |
| ▸ | FAP | Q12884 | 11/20 | 0.61 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.61 |
| ▸ | PITRM1 | Q5JRX3 | 5/20 | 0.53 |
| ▸ | PREP | P48147 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13417269 | 0.84 | DPP4 (0.66) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL13347200 | 0.84 | DPP4 (0.66) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL8287929 | 0.84 | DPP4 (0.66) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL8288237 | 0.83 | DPP4 (0.64) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL13347232 | 0.83 | DPP4 (0.64) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL13417319 | 0.83 | DPP4 (0.64) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL8288241 | 0.83 | DPP4 (0.64) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL13417322 | 0.83 | DPP4 (0.64) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL13347234 | 0.83 | DPP4 (0.64) | DPP4DPP9DPP8FAPDPP7 | |
| SCHEMBL8287957 | 0.77 | DPP4 (0.63) | DPP4DPP9DPP8FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286365-A1 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20090186817-A1 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186817-A1 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME | DNPEP, PEPD, VIP | DPP4 9/4885DPP9 8/4885DPP8 12/4885 |
| US-20100286365-A1 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | DNPEP, PEPD, VIP | DPP4 11/4885DPP9 6/4885DPP8 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.